Clinical Research Directory
Browse clinical research sites, groups, and studies.
Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia
Sponsor: China Medical University Hospital
Summary
Previous study found that some NMDA-enhancing agent was able to augment efficacy of clozapine for clinical symptoms but not cognitive function in the treatment of ultra-resistant schizophrenia. In addition, several drugs with anti-inflammatory properties have been tested in clinical trials for the treatment of schizophrenia. Whether a drug with anti-inflammatory property can strengthen the efficacy of an NMDA-enhancer (NMDAE) in the treatment of ultra-resistant schizophrenia remains unknown.
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2022-02-23
Completion Date
2027-03
Last Updated
2026-03-24
Healthy Volunteers
No
Conditions
Interventions
NMDAE plus AIFA
Use of an NMDA enhancer plus a drug with anti-inflammatory property for the treatment of ultra-resistant schizophrenia.
NMDAE plus Placebo Cap
Use of an NMDA enhancer plus placebo as a comparator
Locations (1)
Department of Psychiatry, China Medical University Hospital
Taichung, Taiwan